A pharmacokinetic-pharmacodynamic model for individualisation of an oral anticoagulation therapy

Warfarin is one of the most common anticoagulants normally used in oral anticoagulant therapy (OAT), which is prescribed for prevention of thromboembolic events. A major challenge in warfarin therapy is its narrow therapeutic range, which requires frequent monitoring and appropriate dose adjustments to maintain the desired therapeutic effect. Variability in both pharmacokinetics (PK) and pharmacodynamics (PD) responses is ascribed to clinical, genetic and demographic factors. One of the main aims of warfarin research is to learn how to reach target response levels in all patients. A new PK-PD model is here proposed and identified using clinical data. It is shown how the model is capable of representing the behaviour of different genetic classes of subjects.